JP2025521091A - がんの治療のためのｓｍａｒｃａ４タンパク質分解因子としての６，６ａ，７，８，９，１０－ヘキサヒドロ－５ｈ－ピラジノ［１’，２’：４，５］ピラジノ［２，３－ｃ］ピリダジン誘導体 - Google Patents

がんの治療のためのｓｍａｒｃａ４タンパク質分解因子としての６，６ａ，７，８，９，１０－ヘキサヒドロ－５ｈ－ピラジノ［１’，２’：４，５］ピラジノ［２，３－ｃ］ピリダジン誘導体 Download PDF

Info

Publication number
JP2025521091A
JP2025521091A JP2024566379A JP2024566379A JP2025521091A JP 2025521091 A JP2025521091 A JP 2025521091A JP 2024566379 A JP2024566379 A JP 2024566379A JP 2024566379 A JP2024566379 A JP 2024566379A JP 2025521091 A JP2025521091 A JP 2025521091A
Authority
JP
Japan
Prior art keywords
pyrazino
methyl
hexahydro
hydroxyphenyl
dione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024566379A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025521091A5 (enExample
Inventor
エイ ローズ，ジョン
ハワード バッシュ，コリー
メイ，ソン
ラソール バーシュ，クレア
ジュリー ビーム ロス，ダニエル
ロールフィング，カタリーナ
ウー，シャオウェイ
シュバーツバート，アルテム
ポール コームズ，アンドリュー
ルー，リアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prelude Therapeutics Inc
Original Assignee
Prelude Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prelude Therapeutics Inc filed Critical Prelude Therapeutics Inc
Publication of JP2025521091A publication Critical patent/JP2025521091A/ja
Publication of JP2025521091A5 publication Critical patent/JP2025521091A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
JP2024566379A 2022-05-10 2023-05-09 がんの治療のためのｓｍａｒｃａ４タンパク質分解因子としての６，６ａ，７，８，９，１０－ヘキサヒドロ－５ｈ－ピラジノ［１’，２’：４，５］ピラジノ［２，３－ｃ］ピリダジン誘導体 Pending JP2025521091A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263340185P 2022-05-10 2022-05-10
US63/340,185 2022-05-10
PCT/US2023/066755 WO2023220577A1 (en) 2022-05-10 2023-05-09 6,6a,7,8,9,10-hexahydro-5h-pyrazino[1',2':4,5]pyrazino[2,3-c]pyridazine derivatives as smarca4 protein degraders for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2025521091A true JP2025521091A (ja) 2025-07-08
JP2025521091A5 JP2025521091A5 (enExample) 2026-05-18

Family

ID=86771366

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024566379A Pending JP2025521091A (ja) 2022-05-10 2023-05-09 がんの治療のためのｓｍａｒｃａ４タンパク質分解因子としての６，６ａ，７，８，９，１０－ヘキサヒドロ－５ｈ－ピラジノ［１’，２’：４，５］ピラジノ［２，３－ｃ］ピリダジン誘導体

Country Status (10)

Country Link
US (1) US20230365576A1 (enExample)
EP (1) EP4522621A1 (enExample)
JP (1) JP2025521091A (enExample)
KR (1) KR20250011136A (enExample)
CN (1) CN119487036A (enExample)
AU (1) AU2023269778A1 (enExample)
CA (1) CA3252552A1 (enExample)
IL (1) IL316891A (enExample)
MX (1) MX2024013843A (enExample)
WO (1) WO2023220577A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023549341A (ja) * 2020-11-06 2023-11-24 プレリュード・セラピューティクス・インコーポレイテッド Ｂｒｍ標的化化合物及び関連する使用方法
WO2024208300A1 (zh) * 2023-04-07 2024-10-10 南京再明医药有限公司 Brm选择性降解剂化合物
WO2025106472A1 (en) * 2023-11-13 2025-05-22 Regents Of The University Of Michigan Compounds and compositions as smarca2/4 degraders and uses thereof
WO2025113460A1 (zh) * 2023-11-28 2025-06-05 西藏海思科制药有限公司 一种哒嗪并三环衍生物及其在医药上的应用
WO2025193454A1 (en) 2024-03-01 2025-09-18 Prelude Therapeutics Incorporated Brm and brg1 targeting antibody-drug conjugates and methods of use thereof
WO2026090411A1 (en) 2024-10-23 2026-04-30 Prelude Therapeutics Incorporated Brm and brg1 targeting compounds and associated methods of use
CN119504710B (zh) * 2024-11-18 2025-10-17 昆明医科大学 靶向降解PRMT5的PROTACs化合物及其应用
CN121873038A (zh) * 2026-03-16 2026-04-17 南开大学 针对结直肠癌的靶向蛋白水解嵌合体及其制备方法、药物组合物和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657744A (en) 1970-05-08 1972-04-25 Univ Minnesota Method for fixing prosthetic implants in a living body
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5061273A (en) 1989-06-01 1991-10-29 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5350395A (en) 1986-04-15 1994-09-27 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5040548A (en) 1989-06-01 1991-08-20 Yock Paul G Angioplasty mehtod
US4748982A (en) 1987-01-06 1988-06-07 Advanced Cardiovascular Systems, Inc. Reinforced balloon dilatation catheter with slitted exchange sleeve and method
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
CA1322628C (en) 1988-10-04 1993-10-05 Richard A. Schatz Expandable intraluminal graft
US5292331A (en) 1989-08-24 1994-03-08 Applied Vascular Engineering, Inc. Endovascular support device
US5674278A (en) 1989-08-24 1997-10-07 Arterial Vascular Engineering, Inc. Endovascular support device
US6344053B1 (en) 1993-12-22 2002-02-05 Medtronic Ave, Inc. Endovascular support device and method
JP6815318B2 (ja) * 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
JP2023529908A (ja) * 2020-06-09 2023-07-12 プレリュード・セラピューティクス・インコーポレイテッド Ｂｒｍ標的化化合物及び関連する使用方法
JP2023549341A (ja) * 2020-11-06 2023-11-24 プレリュード・セラピューティクス・インコーポレイテッド Ｂｒｍ標的化化合物及び関連する使用方法

Also Published As

Publication number Publication date
KR20250011136A (ko) 2025-01-21
WO2023220577A1 (en) 2023-11-16
MX2024013843A (es) 2025-02-10
IL316891A (en) 2025-01-01
CA3252552A1 (en) 2023-11-16
CN119487036A (zh) 2025-02-18
AU2023269778A1 (en) 2024-12-12
US20230365576A1 (en) 2023-11-16
EP4522621A1 (en) 2025-03-19

Similar Documents

Publication Publication Date Title
US12157735B2 (en) Compounds for targeted degradation of BRD9
US20240018158A1 (en) Brm targeting compounds and associated methods of use
JP2023549341A (ja) Ｂｒｍ標的化化合物及び関連する使用方法
CA3154073A1 (en) Isoindolinone and indazole compounds for the degradation of egfr
TW202313628A (zh) 用於降解突變braf之治療劑
US20230365576A1 (en) BRM Targeting Compounds And Associated Methods Of Use
JP2025532611A (ja) Ｂｒｍ標的化化合物及び関連する使用方法
JP2025538228A (ja) Ｂｒｍ標的化化合物及び関連する使用方法
JP2025525339A (ja) ビキチンリガーゼ結合部分を有するｋａｔ６標的化合物
CN119053600A (zh) 用于治疗癌症的杂环化合物
WO2023287787A1 (en) Brm targeting compounds and associated methods of use
WO2025184459A1 (en) Brm and brg1 targeting compounds and associated methods of use
WO2025101738A1 (en) Brm targeting compounds and associated methods of use
US20250074916A1 (en) Brm targeting compounds and associated methods of use
EA048707B1 (ru) Brm направленные соединения и связанные способы применения
EA050840B1 (ru) Brm направленные соединения и связанные способы применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260508

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260508